Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Moritz Binder

Showing results (31-40 of 95) with videos related to

Pageof 10
Sort By:
American Journal of Hematology|June 19, 2023
A phase 1/2 of carfilzomib and melphalan conditioning for autologous stem cell transplantation for multiple myeloma (CARAMEL)Alissa Visram, Suzanne R Hayman, Angela Dispenzieri, et al.
Nature Communications|March 18, 2022
Oncogenic gene expression and epigenetic remodeling of cis-regulatory elements in ASXL1-mutant chronic myelomonocytic leukemiaMoritz Binder, Ryan M Carr, Terra L Lasho, et al.
Amyloid : the International Journal of Experimental and Clinical Investigation : the Official Journal of the International Society of Amyloidosis|June 13, 2025
Hepatic involvement in light chain amyloidosis: analysis of 130 patients and predictors of hepatic response and survivalMatthew J Rees, Nadia Toumeh, Angela Dispenzieri, et al.
British Journal of Haematology|February 6, 2023
A three-gene leukaemic stem cell signature score is robustly prognostic in chronic myelomonocytic leukaemiaYu-Hung Wang, Chi-Yuan Yao, Chien-Chin Lin, et al.
Clinical Lymphoma, Myeloma & Leukemia|July 2, 2024
Association of Thrombocytopenia With Disease Burden, High-Risk Cytogenetics, and Survival in Newly Diagnosed Multiple Myeloma Patients Treated With Novel TherapiesCharalampos Charalampous, Utkarsh Goel, Prashant Kapoor, et al.
Leukemia|December 15, 2019
Clinical, molecular, and prognostic correlates of number, type, and functional localization of TET2 mutations in chronic myelomonocytic leukemia (CMML)-a study of 1084 patientsGiacomo Coltro, Abhishek A Mangaonkar, Terra L Lasho, et al.
British Journal of Haematology|May 10, 2026
Predictors of renal response in AL amyloidosis following anti-plasma cell therapy: The impact of baseline serum free light chain levels and light chain isotypeMatthew J Rees, Binoy Yohannan, Susan Geyer, et al.
Blood|June 9, 2025
Eliminating the need for sequential confirmation of response in multiple myelomaJean-Sébastien Claveau, Prashant Kapoor, Moritz Binder, et al.
American Journal of Hematology|January 3, 2022
Impact of achieving a complete response to initial therapy of multiple myeloma and predictors of subsequent outcomeMarcella Kaddoura, Moritz Binder, David Dingli, et al.
Blood Advances|July 1, 2025
From CyBorD to dara-CyBorD, ASCT utilization trends in AL amyloidosis: a 15-year analysisEli Muchtar, Angela Dispenzieri, Francis K Buadi, et al.
Pageof 10

Showing results (31-40 of 95) with videos related to

Sort By:
Pageof 10
American Journal of Hematology|June 19, 2023
A phase 1/2 of carfilzomib and melphalan conditioning for autologous stem cell transplantation for multiple myeloma (CARAMEL)Alissa Visram, Suzanne R Hayman, Angela Dispenzieri, et al.
Nature Communications|March 18, 2022
Oncogenic gene expression and epigenetic remodeling of cis-regulatory elements in ASXL1-mutant chronic myelomonocytic leukemiaMoritz Binder, Ryan M Carr, Terra L Lasho, et al.
Amyloid : the International Journal of Experimental and Clinical Investigation : the Official Journal of the International Society of Amyloidosis|June 13, 2025
Hepatic involvement in light chain amyloidosis: analysis of 130 patients and predictors of hepatic response and survivalMatthew J Rees, Nadia Toumeh, Angela Dispenzieri, et al.
British Journal of Haematology|February 6, 2023
A three-gene leukaemic stem cell signature score is robustly prognostic in chronic myelomonocytic leukaemiaYu-Hung Wang, Chi-Yuan Yao, Chien-Chin Lin, et al.
Clinical Lymphoma, Myeloma & Leukemia|July 2, 2024
Association of Thrombocytopenia With Disease Burden, High-Risk Cytogenetics, and Survival in Newly Diagnosed Multiple Myeloma Patients Treated With Novel TherapiesCharalampos Charalampous, Utkarsh Goel, Prashant Kapoor, et al.
Leukemia|December 15, 2019
Clinical, molecular, and prognostic correlates of number, type, and functional localization of TET2 mutations in chronic myelomonocytic leukemia (CMML)-a study of 1084 patientsGiacomo Coltro, Abhishek A Mangaonkar, Terra L Lasho, et al.
British Journal of Haematology|May 10, 2026
Predictors of renal response in AL amyloidosis following anti-plasma cell therapy: The impact of baseline serum free light chain levels and light chain isotypeMatthew J Rees, Binoy Yohannan, Susan Geyer, et al.
Blood|June 9, 2025
Eliminating the need for sequential confirmation of response in multiple myelomaJean-Sébastien Claveau, Prashant Kapoor, Moritz Binder, et al.
American Journal of Hematology|January 3, 2022
Impact of achieving a complete response to initial therapy of multiple myeloma and predictors of subsequent outcomeMarcella Kaddoura, Moritz Binder, David Dingli, et al.
Blood Advances|July 1, 2025
From CyBorD to dara-CyBorD, ASCT utilization trends in AL amyloidosis: a 15-year analysisEli Muchtar, Angela Dispenzieri, Francis K Buadi, et al.
Pageof 10